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Abstract:  20	  
Ink-jet printing is a versatile, precise and relatively inexpensive method of depositing small 21	  
volumes of solutions with remarkable accuracy and repeatability. Although developed 22	  
primarily as a technology for image reproduction, its areas of application have expanded 23	  
significantly in recent years. It is particularly suited to the manufacture of low dose medicines 24	  
or to short production runs and so offers a potential manufacturing solution for the paradigm 25	  
of personalised medicines. This review discusses the technical and clinical aspects of ink-jet 26	  
printing that must be considered in order for the technology to become widely adopted in the 27	  
pharmaceutical arena and considers applications in the literature. 28	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1. Introduction 35	  
How should medicines be delivered in the 21st century? Should the tradition of mass-36	  
producing dosage forms aimed at the general population remain or is there the opportunity 37	  
to design bespoke medicines, with doses and/or drug combinations tailored to individual 38	  
patients? There is growing awareness of the limitations of mass-produced medicines and at 39	  
the same time new technologies are being developed that offer tantalising glimpses ahead 40	  
of a vision where medicines can be made more personal. One of those technologies is ink-41	  
jet printing, which offers the potential to deposit very small doses of drugs onto unit dosage 42	  
forms. Moreover, printing medicines offers the potential to manufacture individual dosage 43	  
forms, which can vary in dose for each patient. The purpose of this review is to explore the 44	  
potential of printing medicines in developing the paradigm of personalised-dose medicines, 45	  
with specific focus on considering how each step in the printing process might be impacted 46	  
by pharmaceutical requirements. 47	  
 48	  
1.1 Drug delivery and need for personalised medicine 49	  
Personalised medicine has become a frequently used term yet it does not have a clear 50	  
definition. It is often linked to genomics (Fierz, 2004; Lee, 2010), the effects of the genome 51	  
on response to medicines, and so to the potential of identifying patient groups with different 52	  
responses to drugs and tailoring treatments to them. This view of personalised medicine is 53	  
often criticised for being narrow and not providing a holistic view because it excludes 54	  
aspects such as delivery of the active pharmaceutical ingredient (API) (Møldrup, 2009; Fierz, 55	  
2004). Indeed, it has been speculated that the benefits from developments of diagnostic and 56	  
molecular biology might be lost unless more means of personalised medicine delivery are 57	  
developed (Florence and Lee, 2011). Such development will require new methods of 58	  
manufacture, capable of producing products in small numbers. 59	  
 60	  
An alternative definition of personalised medicine is the dosing and delivery of medicines to 61	  
individuals in a safe and effective manner. The Medicines and Healthcare Regulatory 62	  
Authority (MHRA) recognises the importance of correct dose delivery by defining 63	  
personalised medicine as the individualisation of drug therapy in both choice and dose 64	  
(MHRA, 2006; Reidenberg et al. 2003). Crommelin et al. (2011) define personalised 65	  
medicines and note that such therapies are distinct from mass-oriented delivery systems. 66	  
Florence and Lee (2011) also argue that personalised medicine must mean more than 67	  
simply new drugs matched to the genetic profiles of patients; rather it should include an 68	  
enhanced method of delivery of these drugs to patients and patient groups. In essence, 69	  
therefore, personalised medicine covers all aspects of treatments meaning individualised 70	  
dosing delivery systems are important components. 71	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 72	  
According to Hippocrates, treatment of the individual aspects of the patient supersedes that 73	  
of the underlying pathophysiology in his advice to future generations ‘to treat the person not 74	  
the disease’. Such treatment requires more than just efficacious medicines but an effective 75	  
and personalised delivery system consistent with humans being diverse and with a 76	  
continuum of dosing needs, rather than discrete entities which are catered for by the 77	  
currently available oral solid dosage forms which are present in distinct strengths, not 78	  
reflective of the population’s true drug distribution diversity (Florence, 2010).  79	  
 80	  
Oral solid doses are mass-manufactured in predefined strengths, which are chosen during 81	  
early clinical trials to exert a therapeutic effect in the greatest portion of the population 82	  
(Cohen, 2001; Pardeike, 2011; Herxheimer, 1991). An example is the production of 83	  
fluoxetine (Prozac®). The manufacturer chose a dose of 20 mg for mass production as it 84	  
exerted an effect in 64% of the target population; however 54% had shown a beneficial 85	  
effect at 5mg and the lower dose has been reported to result in fewer adverse effects and 86	  
dropout rates during the trials than did the higher dose (Cohen, 1999). 87	  
 88	  
After medicines are introduced, they begin to be used for a wider population and greater 89	  
diversity of indications, and the inflexibility of fixed dose forms begins to appear. An example 90	  
is the antihypertensive atenolol, introduced in 1976 in only 100 mg tablets. Elderly patients 91	  
required lower doses so, in 1980, 50 mg tablets were introduced followed by the release of 92	  
25 mg tablets in 1989 (Herxheimer, 1991). At the individual patient level, Pies (1995) reports 93	  
the case of zolpidem, which was prescribed to an insomniac using the lowest available 5 mg 94	  
dose. The dose did not achieve a sufficient quality of sleep, so the available 10 mg tablet 95	  
was prescribed instead. Adverse effects ensued, diminishing the patient’s acceptability of the 96	  
therapy with the drug. A 7.5 mg dose has been suggested to meet the patient’s need, but a 97	  
tablet of such strength does not exist. 98	  
 99	  
Patients’ responses to doses vary widely and providing such a diverse population with 100	  
limited doses will inevitably result in groups experiencing the desired therapeutic outcome 101	  
and others receiving higher or lower doses than required, causing either adverse effects or 102	  
inadequate therapeutic levels (Cohen, 2002). The prevalence of adverse effects due to 103	  
untailored therapy has been estimated to be anywhere from 75-85% (Cohen, 1999). Discrete 104	  
strengths are inadequate in providing the precise dose needed for the majority of patients, 105	  
as the response can vary 10-30 fold or more amongst those administering the dose (Ma and 106	  
Lu, 2011; Cohen, 1999). 107	  
 108	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Personalisation for paediatric and geriatric patients is in dire demand. Dosing requirements 109	  
change due to the fast changes in physiological and metabolic functions in the former and GI 110	  
pathologies, body fat and renal clearance changes in the latter (Florence, 2010). In the case 111	  
of the elderly, personalisation is further complicated with polypharmacy and co-morbidities; 112	  
patients aged 65 years or more take on average 13 medicines and as many as 28 (Florence 113	  
and Lee, 2011). This further emphasises the need for strict dose control, to reduce the 114	  
potential for interactions and ensure effective treatment. 115	  
 116	  
1.2 Current approaches to dose personalisation  117	  
The ideal personalised dosing method should be simple, accurate, cheap and best suited for 118	  
the greatest number of patients (Wening and Breitkreutz, 2011). Solid dosage forms, like 119	  
tablets, are amenable to personalised dosing by means of splitting; however, this can result 120	  
in variation in the drug content each part contains (Hill et al., 2009). Pharmacists and 121	  
pharmacy students were also unable to split tablets in a way that resulted in an acceptable 122	  
dose variation of the split tablets (Rosenberg et al., 2002; van Riet-Nales et al., 2014). 123	  
Different methods to split tablets will result in excessive variation whether split by hand, 124	  
knife, scissors or tablet splitters (Verrue et al., 2011; Shah et al., 2010; van Riet-Nales et al., 125	  
2014). 126	  
 127	  
Liquid dosage forms are considered to be suitable for personalised dose production by 128	  
volume-dose calculation, assuming a homogenous drug product (Brown et al., 2004). 129	  
Volume is measured by dosing aids usually accompanying the medicine. These aids come 130	  
at an affordable cost but have been associated with a number of potential sources of 131	  
inaccuracies, such as counting errors for drops, shape effects of the spoon on dosing 132	  
accuracy and confusing graduations on syringes and measuring cups (Grießmann et al., 133	  
2007; Walsh et al., 2011; Yin et al., 2010). Furthermore, those methods also require the 134	  
patient’s and/or carer’s dexterity and cognition to dose precisely and accurately (Peek et al., 135	  
2002). 136	  
 137	  
Against this background, ink-jet printing offers significant potential, because it can be used to 138	  
deposit a large range of doses onto generic substrates (such as tablets or oral wafers) with 139	  
fine control of dose. It is also capable of producing single dosage forms and so its 140	  
development could herald a new future for manufacturing personalised doses. There are an 141	  
increasing number of reports in the literature of ink-jet printing being used to manufacture 142	  
medicines (Kolakovic et al, 2013), but for its use to become widespread consideration must 143	  
be given to the specific requirements of manufacturing pharmaceutical products.  144	  
 145	  
	   6	  
2. Ink-jet printing  146	  
Lord Rayleigh first discussed the basics of an ink-jet system in the nineteenth century, 147	  
describing the breaking of a liquid stream (jet) into droplets (Basaran and Suryo, 2007). The 148	  
concept has been developed into technology that can dispense continuous streams of 149	  
droplets, known as continuous ink-jetting (CIJ) (Priest et al., 1997). An alternative method is 150	  
drop-on-demand (DOD) ejection of droplets (Wang and Bokor, 2007), which produces 151	  
precise droplets at high speeds when needed (Elele et al., 2012). Due to its relative 152	  
simplicity, lower cost and high precision, DOD printing is favoured over continuous inkjet 153	  
printing in desktop printer markets, and it is the technology that is most often used in printing 154	  
applications (Le, 1999; Pond, 1996; Jang et al., 2009). The two main technologies of DOD 155	  
printers are piezoelectric and thermal (or bubblejet) printing (Day and Shufflebottom, 2001). 156	  
 157	  
Thermal inkjet printing (TIJ) uses brief heat pulses generated by a resistive element to jet 158	  
fluid (Goodall et al., 2002). Each print head contains a micro-resistor which heats up rapidly 159	  
on receipt of electric pulses, forming a superheated vapor bubble, as shown in Figure (1). 160	  
The vapor bubble expands, forcing out the fluid from the nozzle and producing a droplet. 161	  
The vapor bubble then collapses, creating a partial vacuum that pulls fluid from the ink 162	  
reservoir to refill the thermal inkjet chamber (Meléndez et al., 2008). The temperature at the 163	  
surface of the resistor can reach up to 300 oC, but such high temperatures exist for only a 164	  
few ms and only ca. 0.5% by volume of the sample is exposed, so the technology does not 165	  
usually degrade thermally labile components. 166	  
 167	  
In piezoelectric printing, each nozzle is surrounded by a piezoelectric element usually made 168	  
from lead zirconate titanate (PZT). When a voltage is applied to the element, it deforms, 169	  
creating pressure waves leading to the ejection of the fluid (Sumerel et al., 2006). Once the 170	  
element returns to its normal shape, the nozzle refills with ink, ready to be reactivated 171	  
(Figure 2) (Scoutaris et al., 2011). 172	  
 173	  
Irrespective of the technology, ink-jet printers jet, on demand, a precisely controllable volume 174	  
of solution to definable coordinates on a substrate (Arney, 2010). Where the ‘ink’ is a 175	  
solution of an API, varying the volume of solution jetted and/or changing the concentration of 176	  
the feed solution determines the amount of drug deposited (Bohórquez, 1994). Printing is 177	  
especially valuable in minimising wastage of expensive drugs (Tarcha et al., 2007). Because 178	  
of this versatility ink-jet printing has been used in a wide range of applications, including 179	  
deposition of large human cells (Wilson and Boland, 2003), cartilage fabrication (Cui et al., 180	  
2014), DNA array fabrication (Okamoto et al., 2000), polymer deposition (de Gans et al., 181	  
	   7	  
2004) and in drug discovery (Zhu et al., 2012). Ink-jet printing has also been used as a 182	  
method to load a microneedle array with miconazole (Boehm et al, 2014). 183	  
 184	  
3. Pharmaceutical applications of ink-jet printing 185	  
Ink-jet printing of medicines is growing in popularity, as the increasing number of 186	  
publications over the past two decades shows (Figure 3). One reason for the growing 187	  
popularity of the technique is its versatility in depositing liquids for different applications, the 188	  
relative ease with which it can be controlled by computer and the repeatability with which it 189	  
dispenses volumes of liquid.  190	  
 191	  
The most immediate potential of ink-jetting for personalised medicines is as a technology for 192	  
extemporaneous manufacturing of unit doses. Clinical teams can choose the exact dose 193	  
needed by the patient and then print it in the pharmacy ready for dispensing. Once entered 194	  
into the printer software, the dose can be deposited onto a substrate suitable for human 195	  
administration (such as an oral wafer or tablet core). However, manufacture of medicines is 196	  
an intricate and regulated process involving a number of key elements, including ensuring 197	  
stability, dose and sterility and must be performed under conditions of good manufacturing 198	  
practice (GMP). The key steps in the printing process must be considered and understood 199	  
within this manufacturing framework. 200	  
 201	  
3.1 Before Printing 202	  
The first requirement is to formulate the API into a solution with suitable properties to be 203	  
jetted by the print head. Clearly, the physicochemical properties of the solution will be 204	  
dependent upon the printer system used and whether it is of the thermal or piezoelectric 205	  
type. Issues arising from suboptimal formulation include puddling (ink rushing with 206	  
momentum overfilling drop generators and nozzles), ink spooling (coalescing of drops upon 207	  
printing) and feathering (excessive spreading) (Stringer and Derby, 2010; Bohórquez, 1994). 208	  
Solvent selection is also critical and is usually dependent on drug solubility. A wide range of 209	  
solvents has been printed, Table 1. One point to note is that in general aqueous solutions 210	  
are more easily jetted with a thermal printer while PZT systems are more suited to organic 211	  
solvents. Raijada et al., (2013) make the sensible suggestion that the concentration of the 212	  
drug should be kept below its solubility to reduce the risk of clogging of the nozzles. 213	  
 214	  
The viscosity and surface tension of any solvent mixture are very important. The surface 215	  
tension should be high enough to enable the formation of spherical droplets and to resist 216	  
leakage from the print head when the printer is not in operation. The viscosity should be low 217	  
enough that the fluid can be jetted but sufficiently high that it is not ejected to early, which 218	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can lead to the formation of a tail, producing satellite droplets (Pardeike et al., 2011; 219	  
Hirshfield et al., 2014). Satellite drops (also known as secondary drops) not only affect 220	  
formation of the primary droplet, but may also impact the location of drug deposition on the 221	  
substrate. It is important that drops land in their designated coordinate on the substrate, 222	  
because otherwise dose uniformity cannot be assured. Ideally a satellite drop would 223	  
recombine with the primary drop or fall not far away on the substrate (Shimoda, 1996; 224	  
Hirshfield et al., 2014). Viscosity and surface tension also affect the refilling phase of the 225	  
drop generator as the solution passes through spouts into the nozzle firing chambers 226	  
(Bohórquez, 1994). 227	  
 228	  
Clearly, the ranges of suitable values for surface tension and viscosity will depend on the 229	  
printer being used. Table 1 shows a list of drugs and formulations that have been printed, 230	  
and their viscosities and surface tensions. Figures 4 and 5 show the viscosity and surface 231	  
tension values for solutions against the technology used to print them; no obvious patterns 232	  
are seen for the different printers involved, which means solutions must be optimised in each 233	  
case. Of course, this assumes the parameters of the printer are fixed. Some printer systems 234	  
allow user-control of the parameters (such as the droplet generating wave-form or the 235	  
pressure above the print solution) and so can be tuned to print a particular solution (Pond, 236	  
1996). For example, a piezoelectric print head is operated by a driving waveform, which can 237	  
be manipulated to control the volume of droplet dispensed for solutions of different 238	  
viscosities and surface tensions (Doraiswamy et al., 2009).  239	  
 240	  
Excipients may be added to the solvent to obtain a solution with suitable viscosity and 241	  
surface tension. Glycols such as propylene glycol (PG), polyethylene glycol (PEG) and 242	  
glycerol are the most commonly used viscosity modifiers (Genina et al., 2012; Genina et al., 243	  
2013a; Sandler et al., 2011). The compatibility between the chosen glycol and the jetting 244	  
liquid should be inspected. Genina et al. (2012) found that riboflavin, which is highly soluble 245	  
in water, precipitated in the presence of polyethylene glycol; glycerol was thus used instead. 246	  
An additional benefit of using glycols is their role in reducing the evaporation of the solvent, 247	  
as they act as humectants (Raijada et al., 2014). Rapid evaporation of the solvent can lead 248	  
to the clogging of the nozzle due to the precipitation of the components of the formulation at 249	  
the nozzle’s tip. Polyethylene glycol, however, has been reported to have central nervous 250	  
system-related adverse side effects in children in large doses (Walsh et al., 2011).  251	  
 252	  
Ethanol has been used at high concentrations in a number of studies (for instance, 60% v/v, 253	  
Raijada et al., 2013; 80% v/w Meléndez et al., 2007; and 95% v/v, Scoutaris et al., 2011). 254	  
FDA guidelines stipulate that medicines should not produce a blood concentration of more 255	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than 25mg/100ml of ethanol, and over-the-counter preparations of ethanol cannot contain 256	  
more that 5% v/v ethanol. Ethanol is a central nervous system depressant (Zuccotti and 257	  
Fabiano, 2011) and so it is desirable to avoid its use in formulations. 258	  
 259	  
From a pharmaceutical perspective, the shelf-life of the jetting liquid should extend beyond 260	  
the time required for production of many doses but the issue of stability is often not the focus 261	  
of the literature. A notable exception is the study by Pardeike et al. (2011) who evaluated the 262	  
stability of a nanosuspension for the deposition of the poorly-water soluble drug folic acid.  263	  
 264	  
3.1.1 Dose flexibility 265	  
The ability to dispense a wide range of doses covering different patient populations is one 266	  
requirement of a successful flexible dosing system (Wening and Breitkreutz, 2011). A dosing 267	  
model defines the relationship between an independent variable and the final formulation 268	  
and may be limited by the capacity of the printer. An example of a model with fixed 269	  
limitations is provided by Genina et al. (2013b), in which the spaces between deposited 270	  
droplets are varied to control the total dose. The limited selection of settings controlling the 271	  
drop spacing ultimately fixed the range of doses that could be printed. Conversely, Buanz et 272	  
al. (2011) found a linear relationship between the concentration of the jetting solution and 273	  
the resulting dose. Despite the narrow range of the dose achieved, in theory the system 274	  
could be set up to print any desired dose, by careful selection of the jetting solution 275	  
concentration. 276	  
 277	  
Another parameter that has been used to control the dose deposited is to change the area 278	  
printed (Genina et al., 2013b; Buanz et al., 2011). When deposited onto an orodispersible 279	  
film, the medicine needs to achieve a therapeutic dose in an area with administrable 280	  
dimensions (Dixit and Puthli, 2009). The administrable area of orodispersible films ranges 281	  
from 1 – 20 cm2, with children aged 6 months and above being able to take films of 6 cm2 282	  
(Bala et al.,2013; Orlu-gul et al., 2014).  283	  
 284	  
3.1.2 Substrates 285	  
Substrates are an administrable carrier on which the drug solution is printed. For oral 286	  
administration it is important that the substrate can be ingested. While the ability to jet many 287	  
drugs has been demonstrated, some studies do not deposit the active onto substrates fit for 288	  
human consumption. Table 2 lists the substrates used in the literature. The use of a range of 289	  
different substrates, including edible substrates such as icing sheets, polymeric and starch 290	  
films and non-edible substrates, such as paper and acetate, has been reported.  291	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Initial studies usually focus on the practical and technical aspects of printing particular 292	  
solutions with less attention given to the substrate. However, as printed dosage forms 293	  
progress in development, consideration of edible substrates is vitally important. It is also 294	  
becoming evident that the nature of the substrate can determine the polymorphic form of any 295	  
crystals produced as the solvent evaporates. For instance, Hsu et al (2013) noted that the 296	  
substrate affected the crystallisation of naproxen when printed onto various solid amorphous 297	  
dispersions while Buanz et al (2013) used ink-jet printing as a screening method for isolating 298	  
pharmaceutical co-crystals. 299	  
 300	  
As the field grows and ink jetting is established as a method of dispensing medicines, 301	  
expanding on patient-acceptable edible substrates will be the next step in the development 302	  
of individualised doses. The acceptability of the dosage form is a key element in compliance 303	  
to the therapy and can influence the safety and efficacy of the therapy (EMA, 2011). A future 304	  
opportunity is the capacity for the substrate choice to influence the release profile of the 305	  
administered medicine, assuming an ingestible dosage form is produced. The impact of 306	  
employing substrates of different flavours could also be of potential for orodispersible 307	  
substrates.  308	  
 309	  
3.2. During printing 310	  
3.2.1 Dose and placement accuracy 311	  
One of the advantages of inkjet printing is the precise deposition of liquids, both in terms of 312	  
volume and placement (Akagi et al., 2014). Placement accuracy refers to the printer’s ability 313	  
to place drops on the desired coordinates of a substrate with accuracy; this factor is relevant 314	  
both in terms of controlling dose but also in terms of appearance. Printers deliver droplets 315	  
consistently within small tolerances. For instance, HP’s Optical Media Advance Sensor 316	  
(OMAS) achieves placement accuracy of ±0.1 mm (Casaldàliga et al., 2011). Dosing 317	  
accuracy in the drug delivery context refers to the deviation of the predicted dose from the 318	  
observed one. Ink-jet printers would be expected to deposit solutions with very high 319	  
accuracy and, indeed, many studies do report low standard deviations, often less than 5% 320	  
(Hirshfield et al., 2014; Buanz et al., 2011; Raijada et al., 2013; Sandler et al., 2011).   321	  
 322	  
However, deviations in printed dose have been reported in the literature. For instance, 323	  
Buanz et al. (2011) attempted to increase the amount deposited onto a substrate by placing 324	  
it back into a printer multiple times. A clear deviation from the predicted dose was seen and 325	  
it was argued that this was due to the contact of the substrate with the rollers of the printer.  326	  
Genina et al. (2013a) observed high standard deviations in deposited drugs that were 327	  
unacceptable (maximum deviations of 11.8%, 24.3% and 34.9% for copy paper, acetates 328	  
	   11	  
and orodispersible films respectively). It was also argued this was due to smearing from 329	  
printer head from printing multiple passes. Similarly, Genina et al. (2013b) used a PZT 330	  
printer to deposit solutions of loperamide and caffeine on edible substrates. The maximum 331	  
loperamide variation was 11.5% exceeding the pharmacopoeial limits of 5% (BP, 2014a). 332	  
The variation for caffeine was much lower at 3.6%. When theophylline was printed onto a 333	  
range of substrates the relative standard deviations were (RSD) ± 5.1%, ± 6.3 and ± 6.25 for 334	  
copy paper, coated paper and PET films substrates respectively. All were outside the BP 335	  
content variation limits of ±5% for theophylline tablets (BP, 2014b; Sandler et al., 2011). A 336	  
wide variation in the dose dispensed could potentially compromise the therapeutic outcome. 337	  
It is especially important when printing actives with a narrow therapeutic index, a subgroup 338	  
for which ink-jet printing is ideally suited. 339	  
 340	  
Many of the publications printed on copy paper. Genina et al. (2013a) found that printing on 341	  
copy paper produced low standard deviations, potentially due to the absorptive nature of the 342	  
substrate; with copy paper designed for printing, the ink can penetrate into the paper 343	  
avoiding smearing. This perhaps highlights an area for future consideration; to develop 344	  
substrates that readily absorb printed solutions. It is important to note here that many of 345	  
these studies used off-the-shelf printers that are not designed for printing pharmaceutical 346	  
solutions, but the principle remains that an ink-jet printer jetting a solution with optimal 347	  
physicochemical properties should better the BP limits in the majority of cases. 348	  
 349	  
1. 3.2.2 Dose printing time 350	  
This is defined as the time required to produce the final dosage form and it is a relevant 351	  
criterion because extemporaneous dispensing can be inconvenient for patients if waiting for 352	  
a lengthy amount of time is involved. Since printing technology has evolved to produce prints 353	  
at high speed, most reports cite short times for dose production. Meléndez et al. (2007) 354	  
calculated that to deposit 8mg of API onto 5.08cm x 1.27cm (2”x0.5”) substrate took a total 355	  
of 2 minutes, while Genina et al., (2013a) took only a few seconds to print a row of five 356	  
16mm x 26mm rectangles. Tarcha et al., (2007) jetted fenofibrate onto a stent; they 357	  
determined that the whole process, on average, took between 6.5 and 7 minutes using a 358	  
PZT printer, although the actual dispensing of the drug itself took less than 2 minutes. 359	  
Raijada et al., (2013) conversely, reported printing samples overnight. 360	  
 361	  
The throughput (total volume deposited per unit time) and therefore the printing time 362	  
depends on the printer system used, the dose and the jetting patterns (Beeson, 1999); 363	  
 364	   𝑇ℎ𝑟𝑜𝑢𝑔ℎ𝑝𝑢𝑡 ∝ 𝑁𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑛𝑜𝑧𝑧𝑙𝑒𝑠   ∙ 𝑓𝑖𝑟𝑖𝑛𝑔  𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦  365	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Equation 1 366	  
 367	  
The drop generation speed (measured in Hertz) has been increasing as technology has 368	  
developed to minimise the jetting time. For example, for TIJ it has grown from 6.25kHz 369	  
(Shimoda, 1996) to10 kHz (O’Horo et al. 1996) and then 36 kHz (Bruch, 2002). Modern 370	  
printers can function at even higher frequencies and purpose-built high throughput PZT 371	  
printers are able to generate droplets at 100 times greater than the conventional printers, 372	  
(Ehtezazi et al., 2014). The number of nozzles has also increased, with TIJ printers often 373	  
reporting higher nozzle counts and packing density per the same unit area than PZT printers 374	  
(Wang and Bokor, 2007). 375	  
 376	  
3.2.3 Maximum achievable dose 377	  
Once printing is initiated, it is important to achieve a dose that can produce the therapeutic 378	  
level required to achieve the clinical outcome. Printers are designed to dispense low 379	  
volumes of intensely coloured inks (Gregory, 1996). This may have contributed to some of 380	  
the trials not achieving therapeutic levels, Table 3. Many studies did, however, achieve 381	  
doses within the therapeutic range, albeit slightly limited. For example, Naproxen was 382	  
dispensed by Hirshfield et al. (2014), but the dose achieved would only be suitable for a child 383	  
weighing 2kg. Buanz et al. (2011) were able to dispense a dose suitable for a child up to 384	  
50kg. Scoutaris et al. (2011) dispensed a felodipine dose within a suitable therapeutic range, 385	  
although the dose dispensed was indicated for the elderly and was only an initial dose.  386	  
Finally, Genina et al. (2013a,b) were able to dispense therapeutic doses of rasagiline and 387	  
loperamide.  388	  
 389	  
3.3 After Printing 390	  
A number of factors must be considered once the printing process has been completed. 391	  
These include consideration, as noted above, of the interaction between the solvent and the 392	  
substrate (blotting), the physical form of the active (an amorphous dispersion or crystalline 393	  
particles), confirmation of dose and stability of the product. Such analyses may be performed 394	  
with differential scanning calorimetry, scanning electron microscopy and X-ray powder 395	  
diffraction. 396	  
 397	  
3.3.1 Dose confirmation 398	  
Ink-jet systems can fail because of nozzle blockage, heater failure or bubble-collapse 399	  
damage (Burke et al., 1996; Kobayashi et al., 1998). TIJ is vulnerable to formation of 400	  
deposits on the heating element, which reduces the drop generating performance, a process 401	  
commonly known as kogation (koga being Japanese for scorching) (Shirota et al., 1996). 402	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Kogation can be reduced using high purity jetting solution components (Reick, 2001), 403	  
deionised water as a solvent (Oka and Kimura, 1996) and a recovery pulse when needed 404	  
(Kobayashi et al., 1998). If a significant proportion of the nozzles fail, it will reduce the total 405	  
dose printed. Inline monitoring of nozzle performance is thus critical for printers used for 406	  
pharmaceutical applications. 407	  
  408	  
Current commercial printers house a number of sensors, for example optical and 409	  
electrostatic detectors fitted in the print-heads, that are able to monitor the nozzles and 410	  
detect any that are non-functioning or malfunctioning. Algorithms are used to instruct other 411	  
nozzles to fire temporarily in lieu of the nozzle in question until the print session is finished, 412	  
when the print-head is recovered by the printer (Bruch, 2002). Such systems can check a 413	  
nozzle in less than 2 ms, (2000 nozzles can take about 5 seconds to check). Those sensors 414	  
and the accompanying algorithms may help reduce the deviation of doses as a result of 415	  
blocked nozzles. 416	  
 417	  
There is, however, an ethical obligation on the part of the pharmacist to inspect and clinically 418	  
check the dose prior to dispensing the dose to the patient (Royal Pharmaceutical Society, 419	  
2011). Such checks should be non-destructive, fast and cheap. Takala et al. (2012) and 420	  
Genina et al. (2012) both dispensed a riboflavin ink formulation, which is an orange coloured 421	  
solution. The colour was used to visualise the deposited solution and might be used to 422	  
quantify the dose deposited. An alternative suggestion is the use of gravimetry, as 423	  
microbalances with high sensitivity can measure the weight of the substances deposited on 424	  
the substrate (Elele et al. 2012). 425	  
 426	  
3.3.2 Drying 427	  
Drying helps in reducing the solvent content and enhances the uniformity of printed doses 428	  
(Carreira et al., 1996; Costello et al. 2010). In traditional printing on paper, absorptive drying 429	  
is the main mechanism at ambient conditions as the liquid penetrates the fibre network of the 430	  
papers (Carreira et al., 1996). Evaporative drying could also be employed to further shorten 431	  
the drying time using hot air convection, keeping temperatures below 50˚C for sensitive 432	  
materials (Voura et al., 2011). It would also be possible to heat the substrate itself. It is 433	  
important to investigate the effect of drying on the physical state of the active, if any, and its 434	  
effect on the therapeutic outcome of the drug. 435	  
 436	  
3.3.3 Printed dose stability 437	  
If the printed dosage form is required for administration at a later time, it is vital to ensure the 438	  
stability of the formulation on the substrate in question. Raijada et al. (2013) explored the 439	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stability of printed piroxicam on paper and found that it was stable for one month under 440	  
conditions of 20-25˚C and 30-40% RH. Scoutaris et al. (2011) and Buanz et al. (2011) both 441	  
stated that if the medicines are to be consumed immediately after fabrication, the impact of 442	  
stability is minimal. Thermochromic (colour changing) containers could be used to indicate 443	  
when the printed doses are stored in temperatures in which shelf life is short (Elele, 1998). 444	  
 445	  
3.4 Administration 446	  
An edible substrate, if it dissolved rapidly upon coming in contact with the salivary secretions 447	  
of the oral cavity, would release its contents and the drug present in the cavity facilitated by 448	  
the movement of the tongue. The dissolved film and its contents would then be swallowed. 449	  
Such films are found to be acceptable dosage form for paediatrics, patients with dysphagia 450	  
and those with fear of choking (Buck, 2013). 451	  
 452	  
Should the taste of the drug (or a film component) be unacceptable the orodispersible route 453	  
of administration may be inconvenient for the patient. In such a case, flavoured substrates 454	  
can be used to facilitate the administration. Another possible administration method would 455	  
be to roll the substrate on which the drug was deposited, and insert it into a hard-shell 456	  
capsule that could be swallowed in a traditional fashion. Using this approach would spare 457	  
the patient the taste of the film but allow personalisation of the dose. However, it would 458	  
mean narrowing the population of patients able to administer the dose. According to the 459	  
European medicines agency (EMA) capsules are only preferentially acceptable in children 460	  
aged 6 years and above (EMA, 2006). Orodispersible dosage forms, on the other hand, are 461	  
acceptable for infants and toddlers (1 month to 2 years, EMA, 2006), with immediately 462	  
dissolving films being suitable for full-term newborn infants (0-28 days, Krause and 463	  
Breitkreutz, 2008).  464	  
 465	  
If rolled into a capsule, dissolution of the carrier film will take place downstream of the 466	  
gastrointestinal tract, at which point the formulation of the film may influence the release 467	  
profile of the ink-jetted medicine if designed for release-controlling purposes. The substrate 468	  
choice can allow an array of tastes for a given dose if a flavoured thin film is used. Other 469	  
substrate matrix types such as hydrophobic matrices can diversify the potential 470	  
pharmacokinetic spectrum of the delivery method.  471	  
 472	  
4. General printing concerns 473	  
4.1 Sterility 474	  
Sterilisation is needed to prevent contaminations of the doses, and the product should be 475	  
manufactured under conditions of GMP. There has been only little mention in the literature of 476	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the effect of sterilising the printer cartridge and printer nozzle in regards to dispensing 477	  
medicines. Using gas plasma treatment, Tirella et al. (2011) sterilised ink cartridges for cell 478	  
printing whereas Lee et al. (2012) cleaned the substrate prior to printing. Roth et al (2004) 479	  
described a method of sterilising the printer by the use of ethylene oxide for the purpose of 480	  
deposition of cell patterning. Buanz et al. (2011), Mueannoom et al. (2012) and Sharma et 481	  
al. (2013) cleaned ink cartridges with distilled water followed by absolute ethanol. Pardeike 482	  
et al. (2011) simply cleaned the nozzle with water, which can be deemed not enough and 483	  
that more sterilisation techniques would need to be implemented.  484	  
 485	  
Thermal ink-jet printers might prove easier to sterilise, because the cartridge and nozzle are 486	  
in one unit and so can be more easily removed or replaced. With common desktop 487	  
piezoelectric inkjet printers, the nozzle is part of the printer and the ink cartridge simply acts 488	  
as a reservoir, therefore, sterilising the nozzles may require sterilisation of the whole printer 489	  
(Arney, 2006). The sterility of the solution is a concern over the duration of cartridge use. 490	  
Ehtezazi et al., (2014) have developed an inkjet device capable of dispensing high 491	  
throughput droplets of liquids using glass which is suggested to cause minimal 492	  
contamination of the liquid being dispensed due to the latter being an inert material. 493	  
 494	  
4.2 Cost considerations 495	  
From the point of view of adoption, Wening and Breitkreutz (2011) devised a classification 496	  
system for personalised dosing of medicines, which classifies the groups of technologies into 497	  
four classes depending on two important properties; cost and dosing flexibility. To minimise 498	  
the cost of producing an ink-jet drug manufacturing system, commercially-available thermal 499	  
ink-jet print-heads, amenable to cheap mass-production could be utilised (Arney, 2006). 500	  
Such systems have proven to be robust since they contain no moving mechanical parts.  501	  
While TIJ technology dominates the market (75% market share), the majority of 502	  
pharmaceutical studies used piezoelectric technology. In general, TIJ printers are cheaper 503	  
and suitable for aqueous solutions while PZT printers are more expensive but can be used 504	  
to jet organic solvents.  505	  
 506	  
4.3 Scale up 507	  
Commercial mass production is always a consideration of any potential new technology, 508	  
although in this case printing probably offers most potential for extemporaneous 509	  
manufacture of relatively small numbers of unit dosage forms. In this context, scale up is not 510	  
an issue. However, should the need arise for ink-jet technology be adopted on a larger 511	  
commercial basis, scale up is relatively straightforward, requiring only an increase in the 512	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number of nozzles (Hirshfield, 2014). This can be achieved with either a larger print head or 513	  
by operating multiple printers side-by-side.  514	  
 515	  
4.4 Success factors for delivery systems 516	  
Florence and Lee (2011) argue that numerous factors contribute to the success of a therapy, 517	  
many of which are not linked to awareness of the genetic profile of the patient. Wening and 518	  
Breitkreutz (2011) argue that for a dosing system to be successful, it must: 519	  
 520	  
- Cover the complete patient population  521	  
- Not require parenteral administration because of patient acceptability and setting-522	  
applicability 523	  
- Promote strong patient adherence 524	  
- Be cost effective  525	  
- Be simple to use 526	  
- Be robust 527	  
 528	  
Ink-jet printing might be a good platform for manufacturing medicines, because of the 529	  
flexibility with which it can deliver medicated solutions for different populations and its ability 530	  
to print on oral films (which have a marketable advantage because they do not require water 531	  
for administration) (Siddiqui et al. 2011). The technology can be exploited further to control 532	  
drug release rates from ingested dosages, for instance by printing a layer of dissolution-rate 533	  
controlling polymers or by combination with other technologies that can control the drug 534	  
release (Genina et al., 2012). 535	  
 536	  
5 Conclusions 537	  
Ink-jet printing is capable of printing solutions and/or nanosuspensions onto a wide range of 538	  
solid substrates, making it a suitable technology for the manufacture of a wide range for oral 539	  
dosage forms. When considering the use of ink-jet printing for pharmaceutical manufacture, 540	  
preformulation studies will be required to ensure solutions have suitable properties for 541	  
jetting; control of viscosity and surface tension are paramount, plus it is important to ensure 542	  
that the API doesn’t precipitate from solution in the printer. Once a solution is optimised for 543	  
printing consideration must be given to the physical form of the drug in the dosage form. 544	  
When the basic formulation has been developed, there is the potential to use the technology 545	  
to fabricate personalised doses and/or drug combinations. 546	  
 547	  
Desktop ink-jet printers are not optimised to print drug solutions but are an effective tool for 548	  
preformulation and evaluative studies. Use of such systems often requires additives to adjust 549	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the physicochemical properties of the solution to match the requirements of the printer. For 550	  
production of medicines for human use the printer technology can be optimised for a 551	  
particular solution. Widespread adoption of ink-jet printing for pharmaceutical manufacture 552	  
will require consideration of GMP. 553	  
 554	  
Ink-jet printing will not replace traditional methods of manufacturing medicines, at least in the 555	  
short term, and it is unlikely to be used for large-scale mass production. The small volumes 556	  
the printer can dispense combined with the low concentrations needed to prevent clogging 557	  
means the technology is more suited to printing drugs with low therapeutic doses.  558	  
Knowledge of whether ink-jet technology could be expanded to print high dose drugs is 559	  
unknown. In the meantime, for low dose drugs with narrow therapeutic windows, ink-jetting 560	  
printing can produce precise, accurate and reproducible doses and offers the potential of 561	  
fabricating doses specific to the patient. 562	  
 563	  
Regulation procedures need to be examined and implemented if the future of inkjet printing 564	  
as a drug delivery method is to progress; this includes methods to confirm dose and sterility 565	  
procedures and consideration of factors affecting point-of-dispensing manufacture. If these 566	  
issues can be overcome, ink-jet technology may herald a new paradigm of personalised 567	  
medicines. 568	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Reference Technology Type of 
liquid 
Ink formulation API Viscosity 
(mPa·s) 
Surface 
tension 
(mN/m) 
Hirshfield et 
al. (2014) 
PZT Solution Ethanol 30:70 
Naproxen/PVP 
- - 
Raijada et 
al. (2013) 
PZT Solution PEG:ethanol 
(40:60) 
Piroxicam 4.9 ± 0.1 27.6 ± 
0.4 
Sandler et 
al. (2011) 
PZT Solution PG–purified water 
(30:70 v/v) 
Paracetamol, 
caffeine, and 
theophylline 
3.1   52.0 ± 
0.4 
Scoutaris et 
al. (2011) 
PZT Solution Ethanol:DMSO 
(95/5) 
Felodipine and 
PVP 
- - 
Lee et al. 
(2012) 
PZT Solution 10%(w/v) PLGA 
solution 
Paclitaxel 5.99 35.4 
Genina et 
al. (2013a) 
TIJ Solution 30:70 (vol%) 
PG:water 
Rasagiline 
mesylate 
≤5  
Genina et 
al. (2013b) 
PZT Solution 40:60 PG:ethanol  Loperamide 3.6 ± 0.2 25.7 ± 
0.7 
Solution 30:70 of 
PG:water 
Caffeine 2.6 ± 0.1 50.7 ± 
1.0 
Buanz et 
al., 2011 
TIJ Solution 10% Glycerol in 
water 
Salbutamol 
sulphate 
1.1 ± 
0.014 
46.4 ± 
2.93 
Pardeike et 
al. (2011) 
PZT Nano-
suspensio
n 
Aqueous 3% 
(w/w) Tween 20 
Folic acid - - 
Genina et 
al. (2012) 
PZT Solution PG:water (30:70, 
vol%) 
Propranolol 2.7 ± 0.1 50.1 ± 
1.0 
Solution Glycerol:Ethanol:
Water (10:10:80, 
vol%). 
Riboflavin 
sodium 
phosphate 
1.6 ± 0.1 49.4 ± 
0.9 
Meléndez et 
al. (2007) 
TIJ Solution Ethanol, water, 
glycerol (80:17:3) 
vol% 
Prednisolone - - 
Takala et al. 
(2012) 
TIJ Solution Glycerol in water Riboflavin 
sodium 
- - 
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phosphate 
Tarcha et 
al. (2007) 
PZT Solution Isobutanol Fenofibrate, 
ABT-578 
- - 
Mueannoo
m et al. 
(2012) 
TIJ Solution Water Salbutamol 
sulphate 
- - 
Goodall et 
al. (2002) 
TIJ Solution 2% PEG 8000: 
0.1% Tween 20 in 
water 
hGH and 
Insulin 
- - 
Sharma et 
al., 2013 
TIJ Solution Water Terbutaline 
sulphate 
- - 
 810	  
Table 1. Types of printers, medicated formulations and properties of the liquid printed 811	  
 812	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Reference Substrate(s) 
Hirshfield et al., 
(2014) 
Hydroxypropyl methyl cellulose (HPMC) films  
Raijada et al., 
(2013) 
Edible icing sheets  
Sandler et al., 
(2011) 
Uncoated paper, coated paper, and polyethylene 
terephthalate (PET) film 
Scoutaris et al., 
(2011) 
Glass cover slip coated in flutec fluid to increase 
hydrophobicity 
Genina et al., 
(2013a) 
Orodispersible films, copy paper, water impermeable 
transparency films 
Genina et al., 
(2013b) 
Icing sheet, PET film, HPC film 
Buanz et al., 
(2011)  
Clear acetate film, Starch film 
Genina et al., 
(2012) 
Uncoated wood-free paper, triple-coated inkjet paper, double-
coated sheet  
Meléndez et al., 
(2007) 
PTFE films over a clear transparency film  
Takala et al., 
(2012) 
Copy paper and photocopy paper 
 815	  
Table 2. Substrates used for medicine printing as reported in the literature 816	  
 817	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Reference Drug Liquid 
Conc. 
(mg/ml) 
Print 
Area 
(cm2) 
Number 
of 
passes  
Total Volume 
(µL/cm2/pass) 
Total 
Dose 
(mg) 
Minimum 
therapeutic 
dose (age 
group) 
Buanz et 
al., (2011) 
Salbutamol 30 4 6 0.06 0.04 15 µg/kg 
(2-18 
years) 
Genina et 
al., (2012) 
Propranolol 50 1 1* 10.06 0.503 2 mg/kg (2-
12 years) 
Riboflavin 31.5 1 1* 10.79 0.34 50 mg (1 
month-18 
years) 
Hirshfield 
et al., 
(2014) 
Naproxen 70 7 1* 22.86 11.2 5 mg/kg (1 
month – 18 
years) 
Raijada et 
al., (2013) 
Piroxicam 5 1 1* 10.02 0.0501 5 mg (6-18 
years, 
under 
15kg) 
Sandler et 
al., (2011) 
Theophylline 5.8 1 1* 13.45 0.078 9 mg/kg (2-
12 years) 
Caffeine 19.3 1 1* 13.99 0.27 2.5mg/kg 
(Neonates) 
Paracetamol 9.9 1 1* 27.27 0.27 60 mg/kg 
(1-3 
months) 
Lee et al., 
(2012) 
Paclitaxel 10 0.367405 1* 0.09 0.00034 - 
Genina et 
al., 
(2013a) 
Rasagiline 
mesylate 
100 6 9 0.39 2.11 1 mg 
Genina et 
al., 
(2013b) 
Loperamide 50 4 1* 12.16 2.431 1 mg (4-8 
years) 
Caffeine 20 4 1* 15.90 1.272 2.5mg/kg 
(Neonates) 
Meléndez 
et al., 
(2007) 
Prednisolone 50 6.4516 60 0.41 8 1-2 mg/kg 
(1 month-
18 years) 
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Tarcha et 
al., (2007) 
Fenofibrate 40 3.2 1* 115.06 14.728 67 mg 
Scoutaris 
et al., 
(2011) 
Felodipine Variable 
(at 1:1 
ratio 
1000) 
NA 1* 2.5** 2.5 2.5mg 
 820	  
Table 3. Doses and volumes of the drugs printed in the literature	  821	  
*	  PZT	  printers	  are	  assumed	  to	  use	  one	  pass	  only	  for	  printing	  822	  
**	  A	  print	  area	  of	  1	  cm2	  is	  assumed	  for	  comparison	  of	  results	  823	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Figure 1. Thermal Inkjet drop generating chamber showing (A) rising of the resistor 829	  
temperature upon receipt of an electrical pulse (B) nucleation due to formation of 830	  
superheated vapour bubble (C) growth of the bubble and deposition of a droplet and 831	  
(D) collapse of the bubble and refilling 832	  
  833	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Figure 2. Piezoelectric drop generating chamber showing (A) the unactivated state (B) 839	  
the movement of the piezo-element upon receipt of an electrical pulse resulting in the 840	  
formation of a droplet and (C) refilling of the chamber  841	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Figure 3. The number of publications on pharmaceutical ink-jet printing recorded on 847	  
Web of Science since 1996. 848	  
 849	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Figure 4. Viscosities of printed solutions from reported literature 855	  
 856	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Figure 5. Surface tensions of printed solutions from reported literature 860	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